Avanza Fonder AB Makes New $7.41 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avanza Fonder AB bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $7,414,000.

Several other hedge funds have also modified their holdings of the stock. Adirondack Trust Co. boosted its holdings in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the period. UMB Bank n.a. grew its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 10 shares in the last quarter. Trust Co. of Vermont increased its stake in Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 12 shares during the period. Brighton Jones LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 14 shares during the period. Finally, Nvwm LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $702.38 on Friday. The stock’s 50 day moving average is $744.16 and its 200-day moving average is $954.41. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $77.18 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 1.60 and a beta of 0.10.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on REGN shares. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research note on Thursday. Bank of America restated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.